Beckmann Amelie, Hüttel Stephan, Schmitt Viktoria, Müller Rolf, Stadler Marc
Department of Microbial Drugs, Helmholtz Centre for Infection Research, Brunswick, Germany.
German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Brunswick, Germany.
Microb Cell Fact. 2017 Aug 17;16(1):143. doi: 10.1186/s12934-017-0756-z.
Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class.
Production of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L. A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L. When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L elansolid A2 but 223.1 mg L elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L).
Reproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules.
最近,有报道称发现了一类大环内酯类化合物——伊兰索利德。这些分子对耐甲氧西林金黄色葡萄球菌以及其他革兰氏阳性菌具有活性。这一事实使这些物质成为未来化学开发的一个有前景的起点。活性阻转异构体A1/A2是由生物合成产物A3通过大环内酯化形成的,但容易开环并随后形成几种不需要的副产物。最近发现,向圣洁几丁质噬纤维菌的培养提取物中添加不同的亲核试剂能够形成新的稳定的伊兰索利德衍生物。此外,将这样的亲核试剂直接添加到培养物中仅导致形成单一的活性伊兰索利德衍生物。由于产物产率低,必须建立生产克级量这些分子的方法,以便能够进一步开发这一有前景的化合物类别。
使用以蔗糖为碳源的合成培养基,使圣洁几丁质噬纤维菌能够生产伊兰索利德A2,最终浓度达到18.9 mg/L。随后进行补料分批发酵,伊兰索利德A2浓度达到55.3 mg/L。当在补料分批发酵中使用葡萄糖作为碳源时,仅产生34.4 mg/L的伊兰索利德A2,但产生了223.1 mg/L的伊兰索利德C1。这一发现并不意外,因为据报道伊兰索利德A1/A2和A3很容易与亲核试剂如色氨酸生物合成的前体邻氨基苯甲酸发生反应。由于亲核试剂可以在体内掺入,因此在相同条件下进行了添加邻氨基苯甲酸的补料分批培养,几乎专一性地形成了伊兰索利德C1(257.5 mg/L)。
在不同的合成培养基中以相对较高的浓度可重复生产伊兰索利德A2和C1,这将允许进一步研究和半合成优化。添加邻氨基苯甲酸能够专一性地生产稳定的伊兰索利德衍生物C1,这减少了非特异性反应导致的产物损失并简化了下游加工。这种衍生物的活性与伊兰索利德A1/A2在同一范围内。因此,该方法可能作为掺入其他亲核试剂和专门设计分子的生物技术生产的模型过程。